Researching and evidencing medical cannabis, CBD & Hemp
The Research Subgroup comprises members from across the Cannabis and Hemp CBD sector in the UK.
The Group exists to commission and carry out research and publish research submissions to further the overall aims of the Council.
For 2022, the main focus of the Research Subgroup is to carry out a Health economic analysis, create condition-specific case studies, research into chemovar profiles in childhood epilepsy, an exploration of real-world evidence (RWE) vs RCTs and to move forward with research in carbon sequestration from hemp.
Areas of focus
This includes Real World Evidence (RWE) and condition-specific research to show the results of current real-world evidence, including a comparison of RWE vs RCTs, a systematic analysis of international databases, survey/s of patient populations and case studies.
Including a cost-benefit analysis of implementing a medical cannabis program on the NHS.
Including cannabis plant research, development and establishment of robust cross-cultivar protocols, the validation of carbon sequestration from hemp.
The group will apply for funding from independent channels to allow more independently funded research to further this work
Meet the Research SubGroup Members
The Group is Chaired by Anne Katrin Schlag, Drug Science.
- 113 Botanicals
- 4C Labs
- AccessKaneh Ltd
- AG Health/Ascension Gardens/Nutree Pharmacy
- Althea/My Access Clinics
- Alto Verde
- AquaLabs Ltd
- Avida Global
- British Cannabis™
- British Hemp Alliance
- Bud and Tender
- Cannabis Patient Advocacy & Support Services
- DPRG Ltd
- Chilam Enterprise Ltd
- Drug Science
- European Industrial Hemp Association (EIHA)
- Hemp Hound
- Hilltop Leaf
- Imperial College
- Lyphe Group
- Medcan support
- Medicann Limited
- PLEA – Patient Led Engagement for Access
- PSI Agri Ltd
- Sana Life Science
- The Cann Group
- The House of Green Limited
- Unyte Group